Comunicado SOR | El Dr. Maximiliano Gordon y el Dr. Federico Furno Sola cuentan la situación que están atrevesando los profesionales de la salud oftalmológica. | By Sociedad Oftalmología de Rosario | Facebook
Consejo Argentino de Oftalmología - 🔤 ABC "MÁCULA:TRÁTAME... SI PUEDES", 26 Y 28 DE OCTUBRE organizado junto a SARyV y coordinado por los Dres. Federico Furno Sola y Daniel Martin. El ciclo
![Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10384-023-00979-8/MediaObjects/10384_2023_979_Fig1_HTML.png)
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE
![Four-month follow up after surgery. Slit-lamp biomicroscopy picture of... | Download Scientific Diagram Four-month follow up after surgery. Slit-lamp biomicroscopy picture of... | Download Scientific Diagram](https://www.researchgate.net/publication/332375708/figure/fig2/AS:746845106089984@1555073157042/Four-month-follow-up-after-surgery-Slit-lamp-biomicroscopy-picture-of-the-right-eye.png)
Four-month follow up after surgery. Slit-lamp biomicroscopy picture of... | Download Scientific Diagram
Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study | PLOS ONE
![Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10384-023-00979-8/MediaObjects/10384_2023_979_Fig3_HTML.png)